Xeris Pharmaceuticals, Inc. (XERS) News
Filter XERS News Items
XERS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XERS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest XERS News From Around the Web
Below are the latest news stories about XERIS BIOPHARMA HOLDINGS INC that investors may wish to consider to help them evaluate XERS as an investment opportunity.
Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202MConsensus $199.7M. Xeris Biopharma (XERS) announced it expects to generate FY24 revenue of $203M, which will exceed previously announced 2024 total revenue guidance of $198M to $202M. The company also anticipates ending 2024 with over $71M in cash, cash equivalents, and short-term investments, generating positive cash flow in the fourth quarter. “We achieved another record quarter of exceptional total revenue growth with revenues expected to be $60 million for the fourth quarter and $203 million |
Xeris Expects to Exceed Full-Year 2024 Financial GuidanceCHICAGO, January 10, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announced 2024 total revenue guidance of $198 million to $202 million. The Company also anticipates ending 2024 with over $71 million in cash, cash equivalents, and short-term investments, generating positive cash flow in the fourth quarter. |
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)CHICAGO, January 06, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on January 2, 2025, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 181,500 shares of its common stock to 19 new employee(s) under Xeris’ Inducement Equity Plan. |
Xeris to Participate in Piper Sandler 36th Annual Healthcare ConferenceCHICAGO, November 26, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 8:00am Eastern Time. |
Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before LongWith the business potentially at an important milestone, we thought we'd take a closer look at Xeris Biopharma... |
Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...Xeris Biopharma Holdings Inc (XERS) reports a robust quarter with significant revenue increases and strategic pipeline progress, despite facing competitive and operational challenges. |
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesWhile the top- and bottom-line numbers for Xeris Biopharma (XERS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue EstimatesXeris Biopharma (XERS) delivered earnings and revenue surprises of 33.33% and 5.09%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Xeris Biopharma: Q3 Earnings SnapshotCHICAGO (AP) — Xeris Biopharma Holdings, Inc. XERS) on Friday reported a loss of $15.7 million in its third quarter. On a per-share basis, the Chicago-based company said it had a loss of 11 cents. |
Xeris Biopharma Reports Third Quarter 2024 Financial ResultsCHICAGO, November 08, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2024. |